SUPER9

Welcome to the Brand page for “SUPER9”, which is offered here for Medicinal preparations for treatment of hemophilia a, viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors; viral systems, gene therapy systems, nucleic acid delivery systems for medical purposes, medicines for the treatment of hemophilia a; pharmaceutical preparations and substances for the treatment of hemophilia a; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of hemophilia a; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapy, gene therapy and cell therapy for the treatment of hemophilia a;super nine;.

Its status is currently believed to be active. Its class is unavailable. “SUPER9” is believed to be currently owned by “UNIQURE IP B.V.”